{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:10:39Z","timestamp":1789175439971,"version":"build-2803163510"},"reference-count":11,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust J Dermatology"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>For patients who do not achieve adequate disease control on biologic monotherapy, or monotherapy with an oral\u2010systemic agent such as methotrexate, combination biologic therapy may be considered. To the best of our knowledge, we report the first case assessing the safety and efficacy of the combination of an interleukin\u201023 (IL\u201023) inhibitor (risankizumab) with a tumour necrosis factor\u2010\u03b1 (TNF\u2010\u03b1) inhibitor (golimumab) in the treatment of psoriasis and psoriatic arthritis. After twelve months of treatment with risankizumab and golimumab, our patient experienced a significant improvement in his psoriasis and psoriatic arthritis without any adverse effects to date.<\/jats:p>","DOI":"10.1111\/ajd.13752","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T18:01:37Z","timestamp":1637690497000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Novel combination biologic therapy for recalcitrant psoriasis and psoriatic arthritis in a medically complex patient"],"prefix":"10.1111","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5270-0517","authenticated-orcid":false,"given":"Sarah","family":"Hanna","sequence":"first","affiliation":[{"name":"Department of Dermatology Royal Prince Alfred Hospital Camperdown NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Youssef","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Royal Prince Alfred Hospital Camperdown NSW Australia"},{"name":"Faculty of Medicine and Health University of Sydney Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Lowe","sequence":"additional","affiliation":[{"name":"Department of Dermatology Royal Prince Alfred Hospital Camperdown NSW Australia"},{"name":"Faculty of Medicine and Health University of Sydney Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,11,23]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15913"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.80"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40579"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110295"},{"key":"e_1_2_5_7_1","first-page":"1098","article-title":"Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center","volume":"12","author":"Heinecke GM","year":"2013","journal-title":"J. Drugs. Dermatol."},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2014.09.002"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14270"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.03.002"},{"key":"e_1_2_5_11_1","first-page":"394","article-title":"Successful treatment of refractory plaque\u2010type psoriasis and psoriatic arthritis with guselkumab and adalimumab combination therapy: a case report","volume":"18","author":"Rathod D","year":"2019","journal-title":"J. Drugs. Dermatol."},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.08.015"}],"container-title":["Australasian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.13752","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajd.13752","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.13752","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T10:01:37Z","timestamp":1733738497000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajd.13752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,23]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1111\/ajd.13752"],"URL":"https:\/\/doi.org\/10.1111\/ajd.13752","archive":["Portico"],"relation":{},"ISSN":["0004-8380","1440-0960"],"issn-type":[{"value":"0004-8380","type":"print"},{"value":"1440-0960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,23]]},"assertion":[{"value":"2021-09-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}